

Supplement 1

Sensitivity Analysis with multivariable regression models for clinical and safety outcomes including the following variables: age, sex, stroke severity (NIHSS at admission), intravenous thrombolysis, pre-event dependency (mRS pre-stroke), **time to EVT*** and Alberta Stroke Program Early CT Score (ASPECTS). Anticoagulation (use of Dabigatran, Rivaroxaban, Edoxaban, Apixaban, Heparin (therapeutic dose), Warfarin) was included in the model for ICH and sICH only.

***time to EVT:** For patients with witnessed onset of symptoms, the time from symptom onset to groin puncture was used as time to EVT. For unwitnessed onset stroke, we considered the time of onset to be the midpoint between last seen well and time of recognition of stroke symptoms by the patient and/or their relatives.

	ICA-T	ICA-I	ICA-E	p for trend
Time to EVT (minutes) – median [IQR]	226 [155 – 345]	262 [189 – 438]	282 [181 – 466]	<0.001

Table S1: Sensitivity Analysis for clinical and safety Outcomes

Clinical Outcomes							
Variables	ICA-T	ICA-I	ICA-E	aOR [95%-CI] ICA I vs. ICA T	P	aOR* [95%-CI] ICA E vs. ICA T	P
mRS at d90 – n (%)	n=1478	n=302	n=235				
- 0	97 (6.6)	20 (6.6)	22 (9.4)	Adjusted cOR 0.97 [0.75 – 1.28]	0.70	Adjusted cOR 0.64 [0.47 – 0.87]	0.01
- 1	133 (9.0)	42 (13.9)	21 (8.9)				
- 2	130 (8.8)	29 (9.6)	23 (9.8)				
- 3	174 (11.8)	42 (13.9)	23 (9.8)				
- 4	215 (14.5)	48 (15.9)	35 (14.9)				
- 5	138 (9.3)	18 (6.0)	21 (8.9)				
- 6	591 (40.0)	103 (34.1)	90 (38.3)				
mRS ≤ 2 at d90 – n(%)	360/1478 (24.4)	91/302 (30.1)	66/235 (28.1)	0.87 [0.59 – 1.30]	0.51	0.66 [0.42 – 1.02]	0.06
mRS ≤ 3 at d90 – n (%)	354/1478 (36.1)	133/302 (44.0)	89/235 (37.9)	1.04 [0.73 – 1.46]	0.84	0.56 [0.38 – 0.83]	<0.01
Early neurologic improvement [†] – n (%)	614/1644 (37.3)	117/326 (35.9)	79/241 (32.8)	0.98 [0.73 – 1.31]	0.88	0.70 [0.49 – 0.98]	0.04
Early Neurologic deterioration [‡] – n (%)	359/1644 (21.8)	71/326 (21.8)	76/240 (31.7)	0.84 [0.59 – 1.19]	0.32	1.61 [1.13 – 2.27]	<0.01
Safety Outcomes							
Variables	ICA-T	ICA-I	ICA-E	aOR [95%-CI] ICA I vs. ICA T	P	aOR* [95%-CI] ICA E vs. ICA T	P
ICH – n (%)	241 (12.4)	35 (9.6)	20 (7.2)	0.72 [0.46 – 1.13]	0.15	0.55 [0.32 – 0.97]	0.04
Symptomatic ICH – n (%)	84/1924 (4.4)	14/360 (3.9)	9/275 (3.3)	0.82 [0.42 – 1.60]	0.56	0.77 [0.35 – 1.70]	0.52
Death during hospital stay – n (%)	490/1793 (27.3)	78/328 (23.8)	74/256 (28.9)	1.33 [0.94 – 1.89]	0.11	2.21 [1.52 – 3.21]	<0.001
Death at d90 – n (%)	591/1478 (40.0)	103/302 (34.1)	90/235 (38.3)	1.02 [0.71 – 1.46]	0.92	1.71 [1.16 – 2.51]	<0.01

*Adjusted Odds Ratio for lower mRS, higher rates of early neurologic improvement / early neurologic deterioration, higher degree of recanalization, higher rates of dissection/perforation, clot migration/embolization, (symptomatic) ICH, death [†]ΔNIHSS ≥4 or NIHSS=0 at 24h, [‡] worsening of NIHSS ≥ 4 at 24h, mRS: modified Rankin Scale, ICH: intracranial hemorrhage